| ORIGINAL ARTICLE |
|
| Year : 2012 | Volume
: 6
| Issue : 1 | Page : 10-13 |
|
|
Hepatitis B core antibody testing in Indian blood donors: A double-edged sword!
RN Makroo, Mohit Chowdhry, Aakanksha Bhatia, Bhavna Arora, NL Rosamma
Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi, India
Correspondence Address:
R N Makroo
Department of Transfusion Medicine, Molecular Biology and Transplant Immunology, Indraprastha Apollo Hospitals, Sarita Vihar, New Delhi - 110 076
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-6247.95043
|
|
|
Background: Until lately, anti-HBc antibodies were considered an effective marker for occult Hepatitis B virus (HBV) infection and have served their role in improving blood safety. But, with the development of advanced tests for HBV DNA detection, the role of anti-HBc in this regard stands uncertain. Materials and Methods: Anti-HBc and HBsAg ELISA and ID-NAT tests were run in parallel on donor blood samples between April 1, 2006 and December 31, 2010 at the Department of Transfusion Medicine, Indraprastha Apollo Hospitals, New Delhi. A positive ID-NAT was followed by Discriminatory NAT assay. Results: A total of 94 247 samples were tested with a total core positivity rate of 10.22%. We identified nearly 9.17% of donors who were reactive for anti-HBc and negative for HBsAg and HBV DNA. These are the donors who are potentially non-infectious and may be returned to the donor pool. Conclusion: Although anti HBc testing has a definite role in improving blood safety, centers that have incorporated NAT testing may not derive any additional benefit by performing anti-HBc testing, especially in resource-limited countries like ours. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
